Live Breaking News & Updates on Flare Index

Stay updated with breaking news from Flare index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AbbVie - Phase 2 Study of Upadacitinib Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active. | June 1, 2023 ....

United States , Roopal Thakkar , Kristin Pawliw , Joan Merrill , Exchange Commission , Lupus Erythematosus National Assessment , Arthritis Clinical Immunology Research Program , European Congress , Oklahoma Medical Research Foundation , Flare Index , Lupus Low Disease Activity State , Medical Research Foundation , Clinical Immunology Research , Allergan Aesthetics , Private Securities Litigation Reform Act , Risk Factors , Quarterly Reports , News Publishing , Abbvie Inc Stock Exchange , Press Release , Everely Abbv Us00287y1091 ,

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary. ....

United States , Joan Merrill , Roopal Thakkar , Upadacitinib Monotherapy , Arthritis Clinical Immunology Research Program , Centers For Disease , European Congress , Lupus Erythematosus National Assessment , Exchange Commission , Oklahoma Medical Research Foundation , Abbvie Deutschland Gmbh Co , British Isles Lupus Assessment Group , Responder Index , Lupus Low Disease Activity State , Flare Index , Clinical Immunology Research , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Final Lock , Key Results , Intended Indication , Systemic Lupus Erythematosus , Adult Systemic Lupus Erythematosus , Disease Activity , Arthritis Care Res ,

Upadacitinib Demonstrates Significant Improvements in Disease Activity, Flare in SLE

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort. ....

United States , Roopal Thakkar , Joan Merrill , European Congress , Arthritis Clinical Immunology Research Program , Lupus Foundation Of America Joan Merrill , British Isles Lupus Assessment Group , Oklahoma Medical Research Foundation , Lupus Foundation , Clinical Immunology Research , Flare Index , Lupus Low Disease Activity State ,